CitM_2019_Planner


1
2	Abstract Highlights 2019
3
4	INDICATION	TRIAL NAME & TAKE HOME MESSAGE	TAKE HOME MESSAGE	ABSTRACT #	VM LINK
5	Lung	Randomized phase III study of pemetrexed/cisplatin (Pem/Cis) versus vinorelbine /cisplatin (Vnr/Cis) for completely resected stage II-IIIA non-squamous non-small-cell lung cancer (Ns-NSCLC): The JIPANG study.	Pemetrexed can be used for adjuvant Therapie	8501	https://meetinglibrary.asco.org/record/173488/video
6	H&N	Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).	Pembro is now part of the first-line therapy: mono or in chemo-immunotherapy	6000	https://meetinglibrary.asco.org/record/171051/video
7	GI	Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.	Olaparib results in significantly improved PFS in patients with metastatic pancreatic cancer and gBRCA mutation. All patients should be tested.	LBA4	https://meetinglibrary.asco.org/record/174488/video
8	GI	ABC-06 \| A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.	mFOLFOX is the new standard 2nd line treatment in CCC	4003	https://meetinglibrary.asco.org/record/173183/video
9	GI	A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial).	RFA has equivant DFS compared to surgery in patients with a maximum of 3 small (up to 3cm) HCC and is now a clearly established option to surgery	4002	https://meetinglibrary.asco.org/record/174776/video
10	Myeloma	Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results.	In combination with VTd Daratumumab moves into front-line treatment of multiple myeloma	8003	https://meetinglibrary.asco.org/record/172374/video
11	GU	Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group tria	Enza is a new alternative to Docetaxel or Abiraterone as addition to high (possibly also low) risk metastatic hormone sensitive prostate cancer	LBA2	https://meetinglibrary.asco.org/record/174531/video
12	GU	TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.	NGS is worthwile in younger and "fit" hormone-refractory prostate cancer patients. Olaparib ist active in BRCA 1/2 mutated patients	5005	https://meetinglibrary.asco.org/record/172904/video
13	GU	Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.	Pembrolizumab plus Axitinib is one of four new alternatives in the front-line treatment of metastatic renal cell cancer and superior to Sunitinib (or Pazopanib)	4500	https://meetinglibrary.asco.org/record/171839/video
14	Sarkoma	ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).	Olaratumab should no longer be used in STS	LBA3	https://meetinglibrary.asco.org/record/174690/video
15	Breast	Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.	Direct start with combination endocrine therapy in premenopausal pts	LBA1008	https://meetinglibrary.asco.org/record/174827/video